Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 4Phase NA 1Phase 1/2 1

Status

Not yet recruiting 2Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 226pembrolizumab 218Carboplatin 174Biopsy 164Cisplatin 157Nivolumab 155Cyclophosphamide 139Radiotherapy 121Paclitaxel 120Gemcitabine 113durvalumab 90Bevacizumab 89Dexamethasone 82Rituximab 81Oxaliplatin 77venetoclax 73atezolizumab 70Doxorubicin 70Docetaxel 66Radiosurgery 65Fluorouracil 65Ipilimumab 64Capecitabine 64Etoposide 62Radiation 59Prednisone 59Cytarabine 59Lenalidomide 56fludarabine 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Maintenance × 90 days × Clear all
NCT07600268 2026-05-20

Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07572929 2026-05-07

PREeMPT

Medical College of Wisconsin

Phase 2 Not yet recruiting
450 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06773936 2026-05-06

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

SWOG Cancer Research Network

Phase 2 Enrolling by invitation
55 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

University of Arkansas

Phase 2 Not yet recruiting
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡